Your browser doesn't support javascript.
loading
Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) with Low-Dose Cisplatin and Doxorubicin in Gastric Peritoneal Metastasis.
Nadiradze, Giorgi; Giger-Pabst, Urs; Zieren, Juergen; Strumberg, Dirk; Solass, Wiebke; Reymond, Marc-André.
Afiliación
  • Nadiradze G; Department of Surgery, University of Magdeburg, Magdeburg, Germany.
  • Giger-Pabst U; Department of Surgery, Ruhr University Bochum, Bochum, Germany.
  • Zieren J; Department of Surgery, Ruhr University Bochum, Bochum, Germany.
  • Strumberg D; Department of Internal Medicine, Oncology and Haematology, Ruhr University Bochum, Bochum, Germany.
  • Solass W; Institute of Pathology, Medical School Hanover, Hanover, Germany.
  • Reymond MA; Department of Surgery, University of Magdeburg, Magdeburg, Germany. marcandre.reymond@elisabethgruppe.de.
J Gastrointest Surg ; 20(2): 367-73, 2016 Feb.
Article en En | MEDLINE | ID: mdl-26511950
BACKGROUND: Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is a novel technique of intraperitoneal chemotherapy. First results obtained with PIPAC in patients with advanced peritoneal metastasis (PM) from gastric cancer (GC) are presented. METHODS: Retrospective analysis: Sixty PIPAC were applied in 24 consecutive patients with PM from GC. 67 % patients had previous surgery, and 79 % previous platinum-based systemic chemotherapy. Mean Peritoneal Carcinomatosis Index (PCI) of 16 ± 10 and 18/24 patients had signet-ring GC. Cisplatin 7.5 mg/m(2) and doxorubicin 1.5 mg/m(2) were given for 30 min at 37 °C and 12 mmHg at 6 week intervals. Outcome criteria were survival, adverse events, and histological tumor response. RESULTS: Median follow-up was 248 days (range 105-748), and median survival time was 15.4 months. Seventeen patients had repeated PIPAC, and objective tumor response was observed in 12 (12/24 = 50 %): no vital tumor cells = 6, major pathological response = 6, minor response = 3. Postoperative adverse events > CTCAE 2 were observed in 9 patients (9/24, 37.5 %). In 3/17 patients, a later PIPAC could not be performed due to non-access. Two patients (ECOG 3 and 4) died in the hospital due to disease progression. CONCLUSION: PIPAC with low-dose cisplatin and doxorubicin was safe and induced objective tumor regression in selected patients with PM from recurrent, platinum-resistant GC. First survival data are encouraging and justify further clinical studies in this indication.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Peritoneales / Neoplasias Gástricas / Carcinoma / Doxorrubicina / Cisplatino / Antineoplásicos Tipo de estudio: Observational_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: J Gastrointest Surg Asunto de la revista: GASTROENTEROLOGIA Año: 2016 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Peritoneales / Neoplasias Gástricas / Carcinoma / Doxorrubicina / Cisplatino / Antineoplásicos Tipo de estudio: Observational_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: J Gastrointest Surg Asunto de la revista: GASTROENTEROLOGIA Año: 2016 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: Estados Unidos